Publicaciones en las que colabora con Edurne San José Enériz (21)

2024

  1. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

2019

  1. Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma

    Hepatology, Vol. 69, Núm. 2, pp. 587-603

2018

  1. Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces

    Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6546-6573

  2. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy

    Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6518-6545

2017

  1. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

    Nature Communications, Vol. 8

2015

  1. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers

    Genome Research, Vol. 25, Núm. 4, pp. 478-487

2012

  1. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia (Blood (2007) 109, 8 (3462-3469))

    Blood

  2. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

    Leukemia, Vol. 26, Núm. 7, pp. 1517-1526

2011

  1. Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family

    British Journal of Haematology, Vol. 155, Núm. 1, pp. 73-83

  2. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in Acute Lymphoblastic Leukemia

    PLoS ONE, Vol. 6, Núm. 2

2009

  1. Epigenetic regulation of MicroRNAs in acute lymphoblastic leukemia

    Journal of Clinical Oncology, Vol. 27, Núm. 8, pp. 1316-1322

  2. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia

    Cancer Research, Vol. 69, Núm. 10, pp. 4443-4453

  3. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

    Molecular Cancer, Vol. 8, pp. 69

2008

  1. BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia

    British Journal of Haematology, Vol. 142, Núm. 4, pp. 571-582

  2. Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium

    European Journal of Heart Failure, Vol. 10, Núm. 11, pp. 1065-1072

  3. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth

    Molecular Cancer Research, Vol. 6, Núm. 12, pp. 1830-1840

  4. Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation

    Leukemia Research, Vol. 32, Núm. 5, pp. 709-716

2007

  1. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia

    Blood, Vol. 109, Núm. 8, pp. 3462-3469

2006

  1. CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia

    Clinical Cancer Research, Vol. 12, Núm. 16, pp. 4845-4850

  2. Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter

    British Journal of Haematology, Vol. 134, Núm. 2, pp. 137-144